Can You Start Lisinopril and Jardiance the Same Day?
Yes, you can safely start lisinopril and Jardiance (empagliflozin) on the same day in adult patients with stable blood pressure and eGFR ≥45 mL/min/1.73 m². Current guidelines explicitly support initiating combination antihypertensive therapy, and there are no contraindications to starting an ACE inhibitor with an SGLT2 inhibitor simultaneously.
Guideline Support for Same-Day Initiation
Combination Therapy is Standard Practice
The 2025 AHA/ACC guidelines strongly recommend initiating two first-line antihypertensive agents simultaneously for patients with stage 2 hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg), ideally as a single-pill combination 1. The 2024 ESC guidelines similarly endorse combination therapy as initial treatment for most patients with confirmed hypertension 2. The 2017 ACC/AHA guidelines note that patients with BP more than 20/10 mmHg above target should start with two agents from different classes 3, 4.
ACE inhibitors combined with other drug classes are explicitly recommended in multiple guidelines. The 2018 Canadian guidelines list ACE inhibitor plus diuretic or ACE inhibitor plus CCB as recommended single-pill combinations 5. Importantly, none of the guidelines require sequential initiation—they support starting both medications together.
SGLT2 Inhibitors and ACE Inhibitors Work Synergistically
The 2022 ADA/KDIGO consensus strongly recommends SGLT2 inhibitors for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m² 6. For empagliflozin specifically, initiation is appropriate with eGFR ≥30 mL/min/1.73 m² for glycemic control or ≥20 mL/min/1.73 m² for heart failure 6. The FDA label confirms empagliflozin's cardiovascular and renal benefits 7.
Research demonstrates safety and efficacy of this combination. A 2022 preclinical study showed that empagliflozin combined with lisinopril reduced blood glucose, proteinuria, glomerular injury, and renal fibrosis more effectively than either agent alone in hypertensive diabetic rats 8. A 2016 clinical trial found empagliflozin reduced blood pressure regardless of concurrent ACE inhibitor/ARB use, with no safety concerns 9.
Practical Considerations for Same-Day Initiation
Monitoring Requirements
When starting both medications simultaneously:
- Check baseline potassium and creatinine before initiation 10
- Expect a transient eGFR dip of 5-10% within the first 1-4 weeks with empagliflozin—this is hemodynamic, not nephrotoxic, and typically recovers 11, 12
- Monitor potassium within 1-2 weeks, especially if eGFR 30-45 mL/min/1.73 m² (lisinopril can increase potassium by ~0.1 mEq/L on average, with 15% experiencing increases >0.5 mEq/L) 10
- Recheck eGFR at 1 month and 3 months to confirm the expected pattern: initial dip followed by stabilization or improvement 12
- Monitor blood pressure within 1-2 weeks as both agents lower BP; empagliflozin reduces SBP by 2-4 mmHg 9
Dosing Strategy
For your patient with eGFR ≥45 mL/min/1.73 m²:
- Lisinopril: Start 5-10 mg once daily (standard initial dose per FDA label) 10
- Empagliflozin: Start 10 mg once daily (standard dose; 25 mg offers no additional renal benefit) 6
- Both can be taken at any time of day for convenience and adherence 2
Common Pitfalls to Avoid
Do not delay SGLT2 inhibitor initiation due to ACE inhibitor use. The 2016 EMPA-REG BP trial specifically demonstrated that empagliflozin's blood pressure and metabolic benefits occur regardless of baseline ACE inhibitor/ARB therapy 9. The combination is complementary, not contraindicated.
Do not panic about the initial eGFR dip. A 2025 real-world study found that 21.6% of patients experienced an eGFR decline >10% at 1 month, but overall eGFR increased by 2.75 mL/min/1.73 m² at 6 months 12. This hemodynamic effect reflects reduced intraglomerular pressure and is associated with long-term renoprotection.
Do not combine with another RAS blocker. The 2025 AHA/ACC guidelines explicitly state that simultaneous use of an ACE inhibitor with an ARB or renin inhibitor is harmful and not recommended 1. Stick with lisinopril alone for RAS blockade.
Counsel patients about volume depletion risk. Both medications can cause volume depletion, particularly in patients on diuretics or with poor oral intake. Advise adequate hydration and temporarily hold medications during acute illness with vomiting/diarrhea 6.
Special Populations
If your patient has diabetes with albuminuria, this combination is particularly beneficial. The 2022 KDIGO guidelines prioritize SGLT2 inhibitors for patients at high risk of CKD progression (those with albuminuria or documented eGFR loss) 13. Adding an ACE inhibitor provides additional antiproteinuric effects 8.
If eGFR is 30-44 mL/min/1.73 m² (stage 3B CKD), you can still initiate both medications, but reduce lisinopril dose to half and monitor more closely 10. Empagliflozin remains appropriate at 10 mg daily 6.
If eGFR <30 mL/min/1.73 m², empagliflozin initiation is not recommended for glycemic control, though it may be continued if already established for heart failure (eGFR ≥20) 6. Lisinopril requires dose adjustment and more frequent monitoring 10.